Cargando…
Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking
BACKGROUND: To report acute and late toxicity in prostate cancer patients treated by dose escalated intensity-modulated radiation therapy (IMRT) and organ tracking. METHODS: From 06/2004 to 12/2005 39 men were treated by 80 Gy IMRT along with organ tracking. Median age was 69 years, risk of recurren...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613141/ https://www.ncbi.nlm.nih.gov/pubmed/18937833 http://dx.doi.org/10.1186/1748-717X-3-35 |
_version_ | 1782163157585756160 |
---|---|
author | Ghadjar, Pirus Vock, Jacqueline Vetterli, Daniel Manser, Peter Bigler, Roland Tille, Jan Madlung, Axel Behrensmeier, Frank Mini, Roberto Aebersold, Daniel M |
author_facet | Ghadjar, Pirus Vock, Jacqueline Vetterli, Daniel Manser, Peter Bigler, Roland Tille, Jan Madlung, Axel Behrensmeier, Frank Mini, Roberto Aebersold, Daniel M |
author_sort | Ghadjar, Pirus |
collection | PubMed |
description | BACKGROUND: To report acute and late toxicity in prostate cancer patients treated by dose escalated intensity-modulated radiation therapy (IMRT) and organ tracking. METHODS: From 06/2004 to 12/2005 39 men were treated by 80 Gy IMRT along with organ tracking. Median age was 69 years, risk of recurrence was low 18%, intermediate 21% and high in 61% patients. Hormone therapy (HT) was received by 74% of patients. Toxicity was scored according to the CTC scale version 3.0. Median follow-up (FU) was 29 months. RESULTS: Acute and maximal late grade 2 gastrointestinal (GI) toxicity was 3% and 8%, late grade 2 GI toxicity dropped to 0% at the end of FU. No acute or late grade 3 GI toxicity was observed. Grade 2 and 3 pre-treatment genitourinary (GU) morbidity (PGUM) was 20% and 5%. Acute and maximal late grade 2 GU toxicity was 56% and 28% and late grade 2 GU toxicity decreased to 15% of patients at the end of FU. Acute and maximal late grade 3 GU toxicity was 8% and 3%, respectively. Decreased late ≥ grade 2 GU toxicity free survival was associated with higher age (P = .025), absence of HT (P = .016) and higher PGUM (P < .001). DISCUSSION: GI toxicity rates after IMRT and organ tracking are excellent, GU toxicity rates are strongly related to PGUM. |
format | Text |
id | pubmed-2613141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26131412009-01-01 Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking Ghadjar, Pirus Vock, Jacqueline Vetterli, Daniel Manser, Peter Bigler, Roland Tille, Jan Madlung, Axel Behrensmeier, Frank Mini, Roberto Aebersold, Daniel M Radiat Oncol Research BACKGROUND: To report acute and late toxicity in prostate cancer patients treated by dose escalated intensity-modulated radiation therapy (IMRT) and organ tracking. METHODS: From 06/2004 to 12/2005 39 men were treated by 80 Gy IMRT along with organ tracking. Median age was 69 years, risk of recurrence was low 18%, intermediate 21% and high in 61% patients. Hormone therapy (HT) was received by 74% of patients. Toxicity was scored according to the CTC scale version 3.0. Median follow-up (FU) was 29 months. RESULTS: Acute and maximal late grade 2 gastrointestinal (GI) toxicity was 3% and 8%, late grade 2 GI toxicity dropped to 0% at the end of FU. No acute or late grade 3 GI toxicity was observed. Grade 2 and 3 pre-treatment genitourinary (GU) morbidity (PGUM) was 20% and 5%. Acute and maximal late grade 2 GU toxicity was 56% and 28% and late grade 2 GU toxicity decreased to 15% of patients at the end of FU. Acute and maximal late grade 3 GU toxicity was 8% and 3%, respectively. Decreased late ≥ grade 2 GU toxicity free survival was associated with higher age (P = .025), absence of HT (P = .016) and higher PGUM (P < .001). DISCUSSION: GI toxicity rates after IMRT and organ tracking are excellent, GU toxicity rates are strongly related to PGUM. BioMed Central 2008-10-20 /pmc/articles/PMC2613141/ /pubmed/18937833 http://dx.doi.org/10.1186/1748-717X-3-35 Text en Copyright © 2008 Ghadjar et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Ghadjar, Pirus Vock, Jacqueline Vetterli, Daniel Manser, Peter Bigler, Roland Tille, Jan Madlung, Axel Behrensmeier, Frank Mini, Roberto Aebersold, Daniel M Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking |
title | Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking |
title_full | Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking |
title_fullStr | Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking |
title_full_unstemmed | Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking |
title_short | Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking |
title_sort | acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613141/ https://www.ncbi.nlm.nih.gov/pubmed/18937833 http://dx.doi.org/10.1186/1748-717X-3-35 |
work_keys_str_mv | AT ghadjarpirus acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking AT vockjacqueline acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking AT vetterlidaniel acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking AT manserpeter acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking AT biglerroland acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking AT tillejan acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking AT madlungaxel acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking AT behrensmeierfrank acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking AT miniroberto acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking AT aebersolddanielm acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking |